TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leishmaniasis
Reports from D. Mansour and colleagues advance knowledge in leishmaniasis
March 18th, 2008
"Corroboration of serology results is essential for restricting the risk of inappropriate antileishmanial prescription. A direct agglutination test (DAT) and a recently developed beta-mercaptoethanol-modified enzyme-linked immunosorbent assay (beta-ME ELISA) based on the use of antigen prepared as described for the DAT were applied to 416 sera from two Sudanese populations with and without clinical evidence of visceral leishmaniasis (VL)," scientists in Netherlands report. "Of 285 sera with the lowest antileishmanial DAT titers (<= 1:100 to 1:1,600), 270 (94.7%) scored comparable minimum beta-ME ELISA absorbance values (<= 0.1 to 0.26). In 117 sera that...
Source: TB & Outbreaks Week (2008-03-18)
|
